Barish Edil to Quinazolines
This is a "connection" page, showing publications Barish Edil has written about Quinazolines.
Connection Strength
0.138
-
Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2013 Jul 15; 86(4):678-85.
Score: 0.110
-
Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and chemotherapy after resection for pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys. 2013 Nov 01; 87(3):458-9.
Score: 0.028